Breast Cancer – BG01-2402

This study is a multicenter, two-stage clinical trial to evaluate the efficacy and safety of utidelone in combination with capecitabine in patients with HER2-negative breast cancer with brain metastases. Patients will be enrolled to receive treatment of utidelone alone or in combination with capecitabine.

The objectives both in stage I and stage II are to evaluate the intracranial and systemic efficacy and safety of utdelone plus capecitabine for the treatment of HER2-negative breast cancer patients with brain metastases.

Inclusion Criteria:

  • Have histologically confirmed HER2-negative metastatic breast cancer
  • Male or female aged ≥18 years
  • Have a life expectancy of at least 3 months
  • Patients must be able to follow the study visit schedule and must be able of sign and give informed consent in accordance with institutional review board
  • Other criteria may apply

Complete the form and our team will reach out soon to help determine your eligibility.

View Study on ClinicalTrials.gov

Trial Interest Form

This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form